Disease landscape

Mesothelioma clinical trials

Get alerts when Mesothelioma trials change

136 active trials 86 recruiting 2 Phase 3 98 sponsors 12 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-16

What changed in the last 30 days

2026-09-16
Primary completion pushed: 2026-06-01 → 2028-12-01
Enrollment reduced: 90 → 35 participants
Completion pushed: 2027-12-31 → 2029-03-01
NCT04969315 TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected… · Portage Biotech · Phase 1/2
2026-09-12
Primary completion pushed: 2026-11 → 2027-11
Completion pushed: 2026-11 → 2027-11
NCT04162015 A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma · Memorial Sloan Kettering Cancer Center · Phase 1
2026-09-04
Primary completion pushed: 2026-12-01 → 2028-07-01
Recruitment resumed after suspension
Enrollment increased: 9 → 15 participants
Completion pushed: 2027-12-01 → 2029-07-01
NCT05960773 Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1… · National Cancer Institute (NCI) · Phase 2
2026-08-26
Enrollment reduced: 55 → 25 participants
Enrollment closed, study ongoing
NCT03007030 Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be… · M.D. Anderson Cancer Center · Phase 2
2026-09-04
Enrollment increased: 200 → 500 participants
NCT04981119 Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell… · A2 Biotherapeutics Inc.

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-07-20 NCT07713732 TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors Treeline Biosciences, Inc. new Phase 1
2026-07-15 NCT07705334 A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic… SHY Therapeutics new Phase 1
2026-07-15 NCT07705074 FAPI PET Imaging - An Exploratory Study Martin Huellner new Phase 1/2

Active trials by phase

Early Phase 1
1
Phase 1
37
Phase 1/2
23
Phase 2
35
Phase 3
2
Not charted: 38 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 136

NCT IDTitleSponsorStatusUpdated
Phase 3
NCT04996017 Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma… Gruppo Oncologico Italiano di Ricerca Clinica Recruiting 2025-03-13
NCT06097728 MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural… AstraZeneca Active, Not Recruiting 2026-07-28
Phase 2
NCT06535607 Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in… AstraZeneca Recruiting 2026-09-11
NCT05960773 Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1… National Cancer Institute (NCI) Recruiting 2026-09-03
NCT05001880 Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma National Cancer Institute (NCI) Recruiting 2026-08-13
NCT07234058 Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus… Intergroupe Francophone de Cancerologie Thoracique Recruiting 2026-08-11
NCT06840834 Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose… Intergroupe Francophone de Cancerologie Thoracique Recruiting 2026-08-10
NCT05647265 Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid… Alliance for Clinical Trials in Oncology Recruiting 2026-08-05
NCT06057935 A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal… Memorial Sloan Kettering Cancer Center Recruiting 2026-07-21
NCT06477419 A Study of Sacituzumab Govitecan in People With Mesothelioma Memorial Sloan Kettering Cancer Center Recruiting 2026-05-28
NCT06503146 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer… National Cancer Institute (NCI) Recruiting 2026-05-19
NCT06638931 Agnostic Therapy in Rare Solid Tumors Instituto do Cancer do Estado de São Paulo Recruiting 2026-04-15
NCT05730816 MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI Brigham and Women's Hospital Recruiting 2025-11-21
NCT04400539 The IMmunotherapy Pleural 5-ALA PDT University Hospital, Lille Recruiting 2025-09-25
NCT06790082 The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma Aalborg University Hospital Recruiting 2025-07-03
NCT05188859 First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in… Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting 2025-05-31
NCT04515836 Olaparib in Patients With HRD Malignant Mesothelioma University of Chicago Recruiting 2025-05-06
NCT06875076 Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in… The First Hospital of Jilin University Recruiting 2025-03-13
NCT06543069 Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting 2024-08-07
NCT03074513 Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors M.D. Anderson Cancer Center Active, Not Recruiting 2026-09-14
NCT03007030 Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be… M.D. Anderson Cancer Center Active, Not Recruiting 2026-08-25
NCT00715611 Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation… Memorial Sloan Kettering Cancer Center Active, Not Recruiting 2026-08-11
NCT01843374 Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With… MedImmune LLC Active, Not Recruiting 2026-07-27
NCT06790706 IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon… Hospices Civils de Lyon Active, Not Recruiting 2026-06-25
NCT06318286 Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural… Hyogo Medical University Active, Not Recruiting 2026-06-10
See all 136 active Mesothelioma trials with filters →

Top sponsors by active trials in this area

National Cancer Institute (NCI) (14) · Memorial Sloan Kettering Cancer Center (9) · A2 Biotherapeutics Inc. (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Novartis Pharmaceuticals (3) · Abramson Cancer Center at Penn Medicine (2) · AstraZeneca (2) · Brigham and Women's Hospital (2) · Dana-Farber Cancer Institute (2) · Intergroupe Francophone de Cancerologie Thoracique (2)

Get alerts when Mesothelioma trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free